CES 2020 : BCA Group to Adopt ProovStation Across Europe
Plans are being implemented for up to 40 inspection portals to be deployed across the BCA Group, starting in February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200109005586/en/
(Photo: ProovStation)
At the 2020 CES in Las Vegas, ProovStation and BCA Group, Europe’s leading vehicle remarketing company, today confirmed a commercial agreement to implement ProovStation inspection portals in BCA auctions and logistics compounds across Europe. The roll-out, which is planned to cover 13 countries, will commence in February.
Thanks to industry-leading artificial intelligence, ProovStation portals will allow BCA to carry out a fully automated damage inspection, including underneath the vehicle, within 3 seconds. As the car drives through the portal, even millimeter-large scratches can be spotted, increasing precision and cost-efficiency.
“We are proud to have been chosen by BCA Group as their site based volume inspection partner. The trust from Europe’s largest seller of used cars is a strong signal of legitimacy for ProovStation and confirms the value of our solutions for the automotive industry in its widest definition. This first large contract is a motivation booster for our team, and we will continue to work hard at revolutionising the vehicle inspection process. We want to turn ProovStation into the international standard in the inspection process for the main market segments: OEM, dealers, rental and logistics service providers” says Cédric BERNARD, CEO of ProovStation.
Jean-Roch PIAT, Divisional CEO of BCA Europe added: “As the leading marketplace for used vehicles across Europe, BCA is providing the power of accurate real-time decision intelligence capability that connects every aspect of buying and selling with BCA, Europe’s largest used vehicle marketplace. ProovStation AI-powered inspection technology allows us to further increase the accuracy of the damage recognition, at unprecedented levels of speed and unit cost to benefit our customers.”
ABOUT PROOVSTATION
ProovStation automates and standardizes the global automotive inspection process. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
OFFICIAL COMMERCIAL LAUNCH AT CES 2020
For its second participation at the CES, the ProovStation start-up returns to Las Vegas with a finalised product, the official launch for mass production, and the determination to win more contracts. ProovStation will present its latest portal at Eureka Park booth 50841.
ABOUT BCA
BCA works with OEMs, fleet operators and dealers to provide the backbone of Europe's automotive supply chain, remarketing 1.4 million vehicles annually.
From technical and logistics services for new vehicles, refurbishment, storage and logistics for the growing used sector and the core remarketing and auction operation, BCA offers the economies of scale and diversity of services to meet the needs of an impressive portfolio of customers.
As the automotive industry faces a period of unprecedented change, BCA is uniquely placed to deliver a range of linked services through the combined infrastructure of de-fleet facilities, vehicle logistics and preparation centres and physical, hybrid and digital remarketing channels.
BCA is investing and innovating today to deliver accurate real-time decision intelligence capability that allow its customers to operate seamlessly in both physical and digital markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005586/en/
Contact information
PROOVSTATION
Laëtitia Guittard
Port: 06 76 13 71 55
laetitia@edifice-communication.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom